FSD Pharma Inc, (CSE:HUGE), announced today the appointment of Dr. Zohar Koren as Head of the Company’s Scientific Advisory Board. This announcement follows the recently announced strategic collaboration of FSD Pharma with SciCann Therapeutics Inc. as its lead scientific platform and center of innovation in Israel, dedicated to the development of disruptive cannabinoid-based therapies backed up by solid science and rigorous clinical studies.
Thomas Fairfull, President and CEO of FSD Pharma, stated “The appointment of Dr. Zohar Koren as Head of the Scientific Advisory Board of FSD Pharma marks a unique and significant milestone on the path of the company to become a true global leader in the field of cannabinoid medicine. Dr. Koren brings with him over 20 years of extensive hands-on experience in the development of pharmaceutical products, mostly in the cannabinoid space, and has deep knowledge and familiarity with the complex paths of designing novel therapies for various indications and bringing them to registration and approval. Under his leadership, the Scientific Advisory Board of FSD Pharma will focus on bringing disruptive science-based cannabinoid therapies to patients, and thus position FSD Pharma as a global leader in the new emerging field of clinically verified and rigorously tested cannabinoid medical products.”
Dr. Koren is co-founder and CEO of SciCann Therapeutics Inc., a Canadian-Israeli speciality pharmaceutical firm dedicated to the development of cutting edge technologies in the pharmaceutical cannabinoid space. Prior to that, Dr. Koren served as VP BD of Mor Research Applications, the technology transfer office of Clalit Healthcare Services, Israel’slargest medical insurer and healthcare provider. He also served as VP BD of Talent Biotechs, a pharmaceutical company, which developed CBD based therapies for GVHD (Graft Vs Host Disease), until its acquisition by Kalytera Inc. in 2017. Previously, Dr. Koren served as Co-founder, CEO and CFO of Cannabics Pharmaceuticals Inc. (OTCQB:CNBX), a developer of cannabis based therapies for oncology patients, and prior to that as Director of Business Development at Aposense Ltd (TASE:APOS), a developer of novel pharmaceutical products in the oncology, CNS and metabolic disease fields.
Dr. Koren holds a Ph.D. and M.Sc. in Protein Science and Computational Biology from the University of Haifa, and a B.Sc. in Mathematics, Physics and Biology from the Hebrew University in Jerusalem. Dr. Koren is a veteran of the prestigious “Talpiyot” program of the Israeli Defence Forces, an elite unit designed to qualify the top technology leader officers of the IDF.
About FSD Pharma
FSD Pharma through its wholly-owned subsidiary FV Pharma, is a licensed producer of marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) having received its cultivation license on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour’s drive from Toronto, FV Pharma management’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FV Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development.
Forward looking information
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the development of the Corporation’s indoor cannabis facility and its business goals and objectives. The forward-looking information contained in this press release is made as of the date hereof, and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.
Thomas Fairfull, President and Chief Executive Officer
Telephone: (905) 686-7079
Neither the Canadian Securities Exchange nor its regulations services accept responsibility for the adequacy or accuracy of this release.
For further information: Investor Relations, Email: IR@fsdpharma.com, Website: www.fsdpharma.com